These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18028004)

  • 1. Tumor necrosis factor as a therapeutic target of rheumatologic disease.
    Ackermann C; Kavanaugh A
    Expert Opin Ther Targets; 2007 Nov; 11(11):1369-84. PubMed ID: 18028004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFalpha as therapeutic target: new drugs, more applications.
    Reimold AM
    Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.
    Cole P; Rabasseda X
    Drugs Today (Barc); 2004 Apr; 40(4):281-324. PubMed ID: 15190385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience].
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Reumatismo; 2007; 59(3):244-61. PubMed ID: 17898886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.
    Criscione LG; St Clair EW
    Curr Opin Rheumatol; 2002 May; 14(3):204-11. PubMed ID: 11981314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
    de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
    Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumor necrosis factor receptors in ankylosing spondylitis.
    Lata M; Hettinghouse AS; Liu CJ
    Ann N Y Acad Sci; 2019 Apr; 1442(1):5-16. PubMed ID: 30008173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathophysiological advances underlying the biotherapeutic revolution in inflammatory rheumatism].
    Mariette X
    Bull Acad Natl Med; 2012 Oct; 196(7):1261-76; discussion 1276-8. PubMed ID: 23815013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.